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ABSTRACT: The mechanism of action (MOA) of the ﬁrst line type-2 diabetes drug metformin remains unclear despite its
widespread usage. However, recent evidence suggests that the mitochondrial copper (Cu)-binding action of metformin may
contribute toward the drug’s MOA. Here, we present a novel biosensing platform for investigating the MOA of metformin using
a magnetic microbead-based agglutination assay which has allowed us to demonstrate for the ﬁrst time the interaction between
Cu and metformin at clinically relevant low micromolar concentrations of the drug, thus suggesting a potential pathway of
metformin’s blood-glucose lowering action. In this assay, cysteine-functionalized magnetic beadswere agglutinated in the
presence of Cu due to cysteine’s Cu-chelation property. Addition of clinically relevant doses of metformin resulted in
disaggregation of Cu-bridged bead-clusters, whereas the eﬀect of adding a closely related but blood-glucose neutral drug
propanediimidamide (PDI) showed completely diﬀerent responses to the clusters. The entire assay was integrated in an
automated microﬂuidics platform with an advanced optical imaging unit by which we investigated these aggregation−
disaggregation phenomena in a reliable, automated, and user-friendly fashion with total assay time of 17 min requiring a sample
(metformin/PDI) volume of 30 μL. The marked diﬀerence of Cu-binding action between the blood-glucose lowering drug
metformin and its inactive analogue PDI thus suggests that metformin’s distinctive Cu-binding properties may be required for its
eﬀect on glucose homeostasis. The novel automated platform demonstrating this novel investigation thus holds the potential to
be utilized for investigating signiﬁcant and sensitive molecular interactions via magnetic bead-based agglutination assay.
KEYWORDS: biosensor, type-2 diabetes, metformin, magnetic beads, agglutination assay, optical imaging, molecular interactions
415 million people have diabetes worldwide, and by 2040, the
number will rise to 642 million according to the latest estimates
of the International Diabetes Federation (IDF); at least 90% of
these patients have type-2 diabetes. Metformin was ﬁrst used in
humans as a type-2 diabetes (T2D) drug in the late 1950s1,2
and is the ﬁrst-line oral treatment for T2D. As it was discovered
before the modern day target-based drug discovery era, its
mechanism of action at the molecular level was not established
before its clinical use and still remains unclear today.1,3,4 A
detailed understanding of its molecular mechanism might lead
to the development of next generation target-based drug for
treating T2D. Regarding the molecular mechanism of
metformin, studies have shown that treatment of liver cells
with metformin leads to reduced mitochondrial respiration5−8
and concomitant reduction of hepatic energy through depletion
of intracellular ATP content.9 Thus, due to lower hepatic
energy, a lower amount of glucose is produced by hepatic cells.
However, the pathway through which metformin reduces the
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mitochondrial respiration is not established yet and is an area of
vigorous research.
This drug has been proven to interact with diﬀerent
metals10−14 and the most stable of these interactions is with
the metal copper (Cu).15,16 Recently the relationship of Cu-
binding to the clinical action of metformin has been under
investigation.16−18 The studies found that metformin binds
with mitochondrial Cu under conditions where it inhibits
mitochondrial respiration. Both Cu2+ and Cu1+ ions are
important ions in electron transport chain enzymes during
ATP production,19−21 and inhibition of these enzymes will
reduce the content of intracellular ATP, resulting in less glucose
production due to lower hepatic energy.7 Up to now, however,
the cell studies with metformin, including those described
above, have depended on high (1−2 mM or more)
concentrations of drug, and therefore it is unclear if they are
related to lowering of the glucose level in blood (anti-
hyperglycemia), which are mediated by low micromolar plasma
concentrations of the drug in plasma. Consequently, in the
current study we have developed tools to measure metformin’s
metal-binding properties at therapeutically relevant concen-
trations.
Magnetic bead-based assays are being utilized for diﬀerent
applications like detection of small molecules,22,23 pathogens,24
and proteins,25,26 as well as PCR ampliﬁcation27 and drug
delivery.28,29 Detection of biomarkers or molecules by
agglutination-based sensing using magnetic beads is being
used for its readout simplicity.30−34 Hence, in our previous
preliminary study,17 the concept of our well-studied magnetic
bead-based agglutination assay22,31,32,34,35 had been utilized for
investigating the eﬀects of metformin on Cu ions as a step
toward understanding the mechanism of metformin. As Cu ions
hardly remain as free ions in the cells36−38 and approximately
35% of them remain bound to cysteine residues,39,40 we
prepared Cu-L-cysteine compound/aggregates using nanosized
magnetic beads to mimic at least 35% of Cu-ligands of the cell,
as these magnetic nanobead (MNB) aggregates will model
protein-bound copper ions particularly well. Addition of
diﬀerent concentrations of metformin caused dissolution of
the aggregates indicating breakage of the Cu-L-cysteine bonds.
The detection of the aggregation−disaggregation phenomena
was performed by a Blu-ray-based optomagnetic system32,34
where the signal peaks were sensitive to the size and
concentration of the aggregates. Thus, the previous agglutina-
tion assay demonstrated that metformin interacts with cysteine-
bound Cu-ligand. A signiﬁcant drawback, however, is that it was
insuﬃciently sensitive to study this property at physiological
concentrations (micromolar) of the drug. In addition, it did not
demonstrate the evidence of relationship between the Cu-
binding action and its glucose lowering property.
In this paper, we present an integrated and automated
biosensing platform with a substantial improvement in
sensitivity compared to our previous work while using
microsized magnetic beads (hereafter represented by “MB”).
These improvements have allowed us to quantify, for the ﬁrst
time, the eﬀects of micromolar concentrations of metformin on
copper-bridged cysteine MB aggregates. To investigate how
well metformin’s Cu-binding action corresponds with its
glucose lowering property, we have compared the Cu-
metformin interactions with an inactive analogue of the drug
propanediimidamide (PDI). Although structurally similar to
metformin, PDI does not show antihyperglycemic behavior in
cells16,17 nor does it exhibit anti-inﬂammatory eﬀects noted
recently for metformin.41 The completely diﬀerent behavior of
PDI compared to that of metformin suggests that metformin’s
Cu-binding action may be required for its glucose-lowering
eﬀect. The overall study has been performed with control
experiments to demonstrate the speciﬁcity of metformin’s
interaction with Cu-bridged MBs. Furthermore, the exper-
imental setup has been improved compared to our previous
study18 by integrating an automated optical imaging unit
(oCelloScope, Philips Biocell) for automated operation of the
entire study, allowing rapid optimization of the Cu-MB clusters.
The usage of microscale beads aided visualization and the
characterization of the clusters using the imaging unit assisted
in the process of the optimization of the assay protocol. The
developed sensing platform has the potential to be an out-of-lab
setting for studying molecular interactions through MB-based
agglutination assay.
■ EXPERIMENTAL SECTION
Materials and Chemicals. The MBs (Dynabeads MyOne
Streptavidin T1, 10 mg/mL) with a surface-coating of streptavidin
used in this study were bought from Life Technologies (Thermo
Scientiﬁc). EZ-Link NHS-LC-LC Biotin was ordered from VWR
(Thermo Scientiﬁc, Product no. 21343) and L-cysteine was purchased
from Merck KGaA (Germany). 50 mM PBS (pH 7.4) and 50 mM
MES (pH 6.0) buﬀer were prepared using Milli-Q water for washing
and sample preparation. The drug vehicle MES buﬀer was prepared by
dissolving 0.488 g MES hydrate (Sigma-Aldrich, product no. M8250;
2-(N-morpholino) ethanesulfonic acid) in 45 mL Milli-Q water while
the pH was adjusted with 1 M NaOH. Cu(NO3)2 purchased from
Sigma-Aldrich was prepared as 0.5 mM solution in MES buﬀer for
performing experiments. Metformin (1,1-dimethylbiguanide hydro-
chloride) and PDI (propanediimidamide dihydrochloride) purchased
from Sigma-Aldrich were prepared at diﬀerent concentration in MES
buﬀer.
Sample Preparation. A solution of 10 mM biotin and a solution
of 0.6 M L-cysteine were prepared using PBS buﬀer (pH 7.4). Next,
the solutions of biotin and L-cysteine were mixed with a volume ratio
of 1:8.5 involving 30 min incubation at room temperature (RT) for
biotinylating the L-cysteine. Next, 10 mg/mL microsized MBs (bead
diameter 1 μm) coated with streptavidin was washed three times with
PBS buﬀer (pH 7.4). After that, the MB solution, biotinylated L-
cysteine solution and PBS buﬀer were mixed with a volume ratio of
1:3.5:5.5 followed by incubation of 1 h with gentle shaking on a shaker
at RT. Finally, the incubated solution was washed three times with 50
mM MES buﬀer and resuspended at a bead concentration of 1 mg/
mL.
Biosensing Platform. In our previous study,18 we used a
microﬂuidic disc-based optomagnetic unit for demonstrating the
eﬀects of diﬀerent concentrations of metformin on the clusters formed
through Cu and magnetic nanobeads (MNB). In the current study, we
have integrated an optical imaging unit34,42 onto the disc-based
optomagnetic unit in order to integrate visualization and quantiﬁcation
of the eﬀects of metformin on the microsized Cu-MB clusters (Figure
1). The setup, in addition, facilitates the integration and automation of
ﬂuidics operation along with automated detection in a user-friendly
fashion.
The current setup (Figure 1) consists of a removable microﬂuidic
disc, a pair of permanent magnets mounted onto the platform for
performing magnetic incubation (MI), and an optomagnetic unit along
with an optical imaging unit for visualization and quantiﬁcation of
nano/microparticles. The disc is attached to a closed-loop motor
(Maxxon Motor, mod. 273756, Switzerland) and controlled using a
LabVIEW (National Instruments) based program which facilitates
automation of the assay and reproducible positioning of the sample.
The optical imaging unit can be moved along both the horizontal and
vertical axes using the instrumental software (Uniexplorer 6.0) which
facilitates automated scanning at the precise positions of the sample/
disc ensuring reproducibility for multiple measurements. The
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automated scanning creates multiple stacks of images using optical
sectioning principle of confocal microscopy resulting in capture of all
the MBs/MB clusters in focus within the scanning window. Using the
instrumental image processing algorithm, the software calculates the
size, i.e., the projected area of each MBs/MB aggregates, and thus gives
the mean MB aggregate size in a sample. Further details of the
scanning principle can be found in refs 34 and 42.
Experimental Procedure. The assay platform in this study was a
microﬂuidic disc made from two layers of poly(methyl methacrylate)
(PMMA) and bonded by a layer of pressure sensitive adhesive (PSA).
The disc (thickness 4.7 mm) contains 24 wells each of which is 4 mm
in depth and 7 mm in diameter (Figure 2a). Thus, 24 individual
experiments can be performed in a single disc, the fabrication of time
of which is <10 min. Further information on the disc fabrication is
presented in the Supporting Information Section S1.
The experimental setup has three deﬁned positions: sample-loading
position, magnetic incubation (MI) position, and scanning position
(Figure 3). First, the microﬂuidic disc was mounted onto the
experimental setup and the well of the disc in which the Cu-MB
sample was to be loaded was placed at the sample-loading position.
Then, a mixed solution of Cu and streptavidin-coated MBs
functionalized with biotinylated L-cysteine (volume ratio 11:1) was
loaded into the particular well of the disc (Figure 2b). After sample
loading, the disc rotated following a rotation routine set by the
LabVIEW program until the sample-ﬁlled well reached the position
between the two permanent magnets (MI position) for performing MI
for 6 min with a magnetic ﬁeld of 60 mT. The MI protocol consisted
of constant incubation (10 s) under the magnet for enhancing
agglutination, followed by clockwise and anticlockwise shaking of the
disc with a speed of 30 rpm for breaking unspeciﬁc binding as well as
facilitating interaction between MBs and Cu. Due to the Cu-chelation
property of L-cysteine, the MBs functionalized with L-cysteine bridge
with Cu through Cu-L-cysteine bond and, thus, causes the formation of
Cu-MB clusters (Figure 2b). The complete MI protocol was run by
the rotation routine made in the LabVIEW program facilitating
reproducibility of the incubation. After the completion of MI, the disc
rotated following the rotation routine for the sample-ﬁlled well to
reach the precise position (scanning position) between the light source
and camera of the optical imaging unit in order to perform scanning of
the clusters. The solution was scanned and the captured images were
analyzed by Uniexplorer 6.0 to quantify the Cu-MB clusters. After
scanning, the sample-ﬁlled well was again positioned to the sample-
loading position using the software in order to add 30 μL of diﬀerent
concentration of metformin/PDI into the Cu-MB clusters (volume
ratio 1:2). After adding the sample, the same rotation routine was
initiated to perform MI followed by scanning to quantify the clusters.
The purpose of the second MI was to further ensure the agglutination
as well as facilitating interaction between Cu-MB clusters and
metformin/PDI while breaking the nonspeciﬁc bindings. The total
assay time including incubation and scanning was approximately 17
min.
■ RESULTS AND DISCUSSION
Interaction of Metformin and PDI with Copper. Our
previous study using MNBs and the optomagnetic unit of the
experimental setup18 showed that Cu-MNB clusters formed
Figure 1. Integrated platform for studying molecular interactions.
Integrated experimental setup consisting of a Blu-ray based
optomagnetic unit, an automated optical imaging unit, and a pair of
permanent magnets on a centrifugal microﬂuidics platform. Details of
the detection units can be found in ref 43.
Figure 2. Schematic of disc and assay design. (a) Schematic of the microﬂuidic disc consisting of 24 wells where the agglutination assay is performed.
(b) Schematic of the agglutination assay. The MBs functionalized with biotinylated L-cysteine forms clusters through L-cysteine-Cu bond after the
addition of Cu2+ followed by magnetic incubation, which are again disaggregated after adding metformin followed by the second magnetic
incubation. Further information on the assay scheme is presented in the Supporting Information Section S2.
Figure 3. Detailed illustration of diﬀerent signiﬁcant positons of the
experimental setup.
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after addition of Cu into the MNB solution, and as millimolar
concentrations of metformin were added, the Cu-MNB clusters
were disaggregated accordingly.
In our current study, we were able to test millimolar and
micromolar doses of metformin due to the optimization of the
assay protocol and the integration of the imaging unit. In the
ﬁrst experiment, we investigated the eﬀect of higher doses
(0.5−50 mM) of metformin on Cu-MB disaggregation (Figure
4). We found that at each concentration tested, metformin
disaggregated the beads.
The control/blank sample containing only MBs suspended in
MES buﬀer shows no MB clusters (Figure 4). Addition of Cu2+
into the control sample followed by ﬁrst MI forms the Cu-MB
clusters. This aggregation phenomena indicates that addition of
Cu2+ along with MI causes the L-cysteine-functionalized MBs to
bind to Cu2+ through the formation of Cu-L-cysteine bond.
Then, the addition of diﬀerent concentrations of metformin
into the Cu2+ sample followed by second MI causes the
breakage of the clusters. As the MBs were aggregated based on
the Cu-L-cysteine bond, this disaggregation phenomena
indicates that metformin has caused the breakage of Cu-L-
cysteine bond.
Next, we investigated the eﬀect of the same concentrations of
PDI on the Cu-MB clusters, to compare with that of metformin
(Figure 5). We found that addition of PDI did not reduce the
Cu-MB clusters at lower concentrations and from 10 mM
onward, PDI increased the size of the clusters. These results
demonstrate that PDI does not break the Cu-L-cysteine bond
like metformin. Although they are structurally similar to
metformin, malonamides like PDI are not antihyperglycemic,44
and thus, these results are consistent there being a link between
the metformin’s Cu-binding action and its antihyperglycemic
properties.
Control Experiments. We performed control experiments
in order to validate that we had measured true eﬀects of
metformin and PDI and their interaction with copper ions. In
order to validate that it is not MI but Cu which forms the
aggregates, a sample containing MES (copper vehicle) and
functionalized MBs with a volume ratio of 11:1 (similar ratio to
the Cu-MB sample) was loaded into the disc followed by ﬁrst
MI which showed no clusters (Figure 6a). Then, MES buﬀer
alone was further added to this solution followed by second MI
to mimic the addition of metformin/PDI into Cu-MB solution.
Even after the second MI, no signiﬁcant clusters were formed,
Figure 4. Eﬀect of adding metformin (Metf) at diﬀerent concentrations into the Cu-MB clusters. (a) Images captured by the optical imaging unit of
diﬀerent MB samples. (b) Corresponding mean area of MB aggregates (calculated by Uniexplorer 6.0) vs diﬀerent MB samples. Error bars indicate
the standard deviation obtained from triplicate measurements. Scale bar: 50 μm. *P < 0.05, **P < 0.01, ***P < 0.001 by one way ANOVA test
compared to Cu2+ sample.
Figure 5. Eﬀect of adding PDI at diﬀerent concentrations into the MB-Cu clusters. (a) Images captured by the optical imaging unit of diﬀerent MB
samples. (b) Corresponding mean area of MB aggregates (calculated by Uniexplorer 6.0) vs diﬀerent MB samples. Error bars indicate that the
standard deviation obtained from triplicate measurements. Scale bar: 50 μm. *P < 0.05, **P < 0.01 by one way ANOVA test compared to Cu2+
sample.
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which shows that it is Cu and not MI which causes the larger
clusters to form (Figure 6a,b).
To validate the eﬀect of metformin/PDI on Cu-MB clusters,
we added 30 μL of MES (drug vehicle) in the Cu-MB clusters
Figure 6. Control experiments to validate that the assay is measuring drug/metal interactions. (a) Images captured by the optical imaging unit
showing a comparison of the MB aggregate size between the ﬁrst and second MI of the control sample after adding 30 μL of buﬀer. (b)
Corresponding mean area of MB aggregates (calculated by Uniexplorer 6.0) vs the control samples. (c) Images captured by the optical imaging unit
showing a comparison of the Cu-MB aggregate size between the ﬁrst and second MI of Cu2+ samples. (d) Corresponding mean area of MB
aggregates (calculated by Uniexplorer 6.0) vs the Cu2+ samples. Error bars indicate the standard deviation obtained from triplicate measurements.
Scale bar: 50 μm.
Figure 7. High sensitivity assay measures metformin/Cu interaction at physiological concentrations of the drug. (a) Images captured by the optical
imaging unit showing a comparison of Cu-MB clusters of the samples with diﬀerent biotin-L-cysteine ratios. (b) Eﬀect of low concentrations of
metformin (Metf) on Cu-MB clusters using the lowC sample. Images captured by the optical imaging unit showing the eﬀects of adding metformin
at diﬀerent concentrations at micromolar range into the Cu-MB clusters. (c) Mean MB aggregate size (calculated by Uniexplorer 6.0) vs diﬀerent
MB samples. The blue line indicates the result of the control experiment which shows that addition of Cu2+ into control/blank sample creates Cu-
MB clusters followed by addition of MES showing no signiﬁcant change. Error bars indicate the standard deviation obtained from triplicate
measurements. Scale bar: 50 μm. *P < 0.05 by one way ANOVA test compared to MES+Cu2+ sample.
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followed by second MI which showed no signiﬁcant change in
cluster size (Figure 6c,d). This vehicle control strongly
indicates that the eﬀects of metformin and PDI are true
drug-dependent eﬀects. Together, these results indicate that Cu
is required to form the large-scale aggregates and that
metformin alone disaggregates these beads.
Assay Optimization to Detect Metformin/Copper
Interaction at Physiological Drug Concentrations. The
peak plasma concentration of metformin is in the region of 25−
50 μM,45 and consequently we were interested in investigating
the metformin/Cu interactions at these lower concentrations.
In order to optimize the assay sensitivity to lower
concentrations of metformin, we focused on the volume ratio
of biotin and L-cysteine during the sample preparation step
because the biotinylated L-cysteine is a signiﬁcant component of
this assay as it functions as a linker between Cu and
streptavidin-coated MBs to enable aggregation. The initial
volume ratio of biotin and L-cysteine was 1:8.5 by which the
millimolar eﬀects of metformin have been demonstrated above.
At this volume ratio, we noted the presence of free MBs as well
as heterogeneous MB clusters of smaller and larger size (Figure
7a) indicating that many of MBs were not suﬃciently
functionalized with L-cysteine, due to insuﬃcient biotinylation
of L-cysteine. Probably because of this heterogeneity, we were
unable to reliably detect eﬀects of low concentrations of
metformin on these MB aggregates. To improve sensitivity, we
hypothesized that there might be an optimal ratio of biotin:L-
cysteine, where most of the MBs would be homogeneously
functionalized with biotinylated L-cysteine, leading to the
formation of Cu-MB clusters of increased homogeneity and
potentially improving assay sensitivity. Optimizing MB
functionalization with L-cysteine through maximizing the
biotinylation of L-cysteine would increase the probability of
MBs agglutinating more speciﬁcally through Cu bridges,
potentially increasing the sensitivity of the assay to
metformin-induced disaggregation. We varied the biotin:L-
cysteine ratio in two stock solutions from 1:8.5 (highC sample)
to 1:4.5 (lowC sample) and 1:2.5 (very lowC sample) by
increasing the volume of biotin. The amount of L-cysteine was
kept constant as reducing cysteine further below would
ultimately result in a failure of aggregates to form. We
compared side by side the Cu-MB clusters formed from MB
samples with these three diﬀerent biotin and L-cysteine ratios
(Figure 7a) and found indeed that the lowC ratio formed
aggregates that were much more homogeneous in size and
densely packed than in the highC sample.
Compared to both of these samples, the very low C sample,
which was prepared by adding a much higher volume of biotin,
resulted in Cu-MB clusters much smaller both in size and in
amount, conﬁrming that saturation with biotin eventually
blocks aggregate formation, likely because the excess amount of
free biotin saturated the binding sites of streptavidin on the
MBs.
We used the improved formulation of the lowC sample to
study the eﬀects of metformin at low concentrations (Figure
7b,c). As before, the addition of Cu2+ into the MB solution
followed by MI resulted in clusters. Further addition of 25 μM
or 50 μM metformin followed by second MI causes the
breakage of the clusters indicating that metformin does interact
with Cu2+ from the Cu-L-cysteine bond, even at micromolar
concentrations. To validate this experiment, MES buﬀer
(instead of metformin) was added to Cu-MB solution followed
by MI, which showed again no signiﬁcant change to the
clusters.
We thus found that the formulation of the lowC sample was
a crucial development to enable visualizing the eﬀect of
metformin in the micromolar range. In future work, we will
continue to pursue further possibilities for optimization in
order to make the assay more sensitive and robust.
■ CONCLUSION AND FUTURE WORK
We have developed an improved experimental setup to study
molecular interactions using magnetic bead-based agglutination
assay. Using this equipment along with the optimized assay, we
demonstrate for the ﬁrst time that metformin interacts with
copper ions at physiologically signiﬁcant concentrations of the
drug. Furthermore, our experiments comparing the eﬀects of
metformin and PDI strongly suggest that metformin’s Cu-
binding property may be linked to its therapeutic drug action.
These results create a platform for future work to further
investigate the eﬀects of metformin directly in blood cells and
hepatic cells at μM concentrations by adaptation of the
magnetic bead-based agglutination assay we have developed.
However, utilization of magnetic bead-based agglutination assay
in raw biological samples (e.g., plasma or cells) is challenging as
endogenous interferents can form unspeciﬁc magnetic bead
clusters decreasing the speciﬁcity and sensitivity of the assay.
Therefore, in our next study with raw biological samples, we
will integrate the biotin-L-cysteine conjugation protocol with
our previously presented30 antifouling surface architecture
development through the formation of a layer of blocking
proteins on the bead surface in order to prevent nonspeciﬁc
aggregate formation under the inﬂuence of the biological
samples. As serum albumin is well-known to minimize protein
aggregation;46 likewise in a previous study,31 the surface of the
MBs ﬁrst would be passivated with a monolayer of human
serum albumin (HSA) for preventing the formation of
undesired protein corona in plasma samples. The HSA
monolayer on the MB surface would be attached to L-cysteine
through biotinylated biorthogonal click conjugation (e.g., Cu-
free click chemistry) forming a multilayered surface structure
over MB surface for such surface structures previously
demonstrated dramatic increase of assay sensitivity as well as
facilitation of speciﬁc cross-linking of the aﬃnity probes in
biological ﬂuids.31,47 The entire assay can be integrated in the
microﬂuidic disc with additional microﬂuidic structures for on-
disc plasma extraction from whole blood sample. For cellular
studies, a ﬂuorescence probe can be added to the MBs with
multilayered surface architecture followed by microinjecting the
conjugate in hepatic (e.g., H4IIE) cells. Thus, the presence of
cellular Cu-L-cysteine is expected to form Cu-bridged MB
clusters inside the cells while quenching the ﬂuorescence.
Adding metformin to the cell medium and its uptake into the
cell will be expected to cause disintegration of the aggregates
while restoring the ﬂuorescence. Hence, the extension of this
study in the future can be performed in raw biological samples
by overcoming the potential challenges of biological interfer-
ences and thus adding further validation to this current study of
metformin’s Cu-binding action at cellular concentrations. In
conclusion, the developed biosensing platform demonstrating
automation, low sample-to-answer time, along with a novel
application, thus paves the way for investigating further
signiﬁcant molecular interactions using the simple readout
concept of agglutination assay in a reliable and user-friendly
fashion.
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